BNP Paribas Asset Management
CORT icon

BNP Paribas Asset Management’s Corcept Therapeutics CORT Stock Holding History

BNP Paribas Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$128K Sell
1,471
-134
-8% -$8.09K ﹤0.01% 1495
2026
Q1 		$64.7K Buy
1,605
+328
+26% +$12.3K ﹤0.01% 1655
2025
Q4 		$44K Sell
1,277
-13,793
-92% -$1.08M ﹤0.01% 1696
2025
Q3 		$1.25M Buy
15,070
+2,052
+16% +$148K ﹤0.01% 675
2025
Q2 		$955K Buy
13,018
+9,488
+269% +$688K ﹤0.01% 764
2025
Q1 		$403K Buy
+3,530
New +$215K ﹤0.01% 818

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Asset Management's CORT Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Corcept Therapeutics (CORT) stake by 8.3% in Q2 2026, selling an estimated $8.09K and leaving 1,471 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #1495.

BNP Paribas Asset Management first reported a position in CORT in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.25M in Q3 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • BNP Paribas Asset Management held 1,471 shares of Corcept Therapeutics worth $128K as of Q2 2026.
  • BNP Paribas Asset Management sold 134 Corcept Therapeutics shares in Q2 2026, an estimated $8.09K.
  • Corcept Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1495 holding.
  • BNP Paribas Asset Management first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • BNP Paribas Asset Management's Corcept Therapeutics position peaked at $1.25M in Q3 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.